ArticleDigestive diseases and sciences2026
Severe Influenza-Related Outcomes in Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy: A Propensity-Matched Cohort Analysis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative efficacy of ustekinumab and vedolizumab in anti-TNF-naive and anti-TNF-exposed patients with Crohn's disease: a matched cohort study.Proceedings (Baylor University. Medical Center) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with active inflammatory bowel disease (IBD) often require immunosuppressive therapy to achieve and maintain remission; however, the impact of these medications on influenza risk and the severity of influenza-related complications remains inadequately characterized.
methodsUsing the TriNetX U.S. Analytics Network, adults (≥ 18 years) with Crohn's disease or ulcerative colitis during the 2022-2023 influenza season were identified. Patients were stratified by disease activity into two cohorts: (1) active IBD, defined by elevated inflammatory markers, initiation of corticosteroids or a new biologic or small-molecule agent, or documented IBD-related symptoms or complications within the prior six months; and (2) inactive IBD, defined by the absence of these features and no recent immunosuppressive therapy. Propensity score matching (1:1) was used to balance baseline characteristics, and Cox proportional hazards models were applied to estimate hazard ratios for influenza-related outcomes.
resultsAfter propensity score matching, each group had 22,784 patients. The incidence of influenza diagnosis was significantly higher in the active IBD group (HR 1.41; 95% CI 1.30-1.52). Hospitalization rates were also increased (HR 2.05; 95% CI 1.89-2.23), as were influenza-related complications (HR 1.36; 95% CI 1.23-1.51). ICU admissions (HR 1.51; 95% CI 1.33-1.72) and mechanical ventilation (HR 1.68; 95% CI 1.32-2.13) were both more frequent in the active IBD group. Use of antiviral medications was higher among patients with active IBD (HR 1.60; 95% CI 1.22-2.10), and overall mortality was modestly increased (HR 1.17; 95% CI 1.02-1.35). Subgroup analysis revealed the highest risk among patients on corticosteroids, followed by JAK inhibitors and anti-IL-23 agents.
conclusionPatients with active IBD had more severe influenza-related outcomes compared with those with inactive IBD. Improving vaccine uptake and prompt evaluation of upper respiratory symptoms during influenza seasons are key to reducing influenza-related risks in immunosuppressed patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.